TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10992311

Group type: EXPERIMENTAL
Intervention: Dural sac anteroposterior (AP) diameter of 10.2 mm at the L3-4, L4-5, or L5-S1 vertebral levels
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Herniated disc with an AP diameter of approximately 3 mm
Number of subjects: 66

Group type: COMPARATOR
Intervention: Comparison of herniated disc AP diameters in symptomatic patients vs. asymptomatic controls
Number of subjects: 66
Study: 9416634

Group type: EXPERIMENTAL
Intervention: Negative priming conditions in Experiment 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative priming conditions in Experiment 2
Number of subjects: 0
Study: 8218682

Group type: EXPERIMENTAL
Intervention: 2 mL immune serum globulin (ISG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5 mL immune serum globulin (ISG)
Number of subjects: 0
Study: 3315600

Group type: EXPERIMENTAL
Intervention: AP-SAC 30U
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hospital administration
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: At-home injection
Number of subjects: 25
Study: 26630416

Group type: EXPERIMENTAL
Intervention: MRI assessment of absence of epidural fat
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: MRI assessment of presence of tortuous caudal nerves
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Grading of compression on preoperative MRI
Number of subjects: 155
Study: 26734916

Group type: EXPERIMENTAL
Intervention: GTR plus LLLT
Number of subjects: 33

Group type: COMPARATOR
Intervention: GTR alone
Number of subjects: 33
Study: 24583792

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with modified HLA‐class I p53 peptides (Arm 1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with Th tetanus toxoid peptide (Arm 2)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination with Th wild‐type p53‐specific peptide (Arm 3)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination (all arms)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dendritic cell (DC)‐based vaccination
Number of subjects: 16
Study: 21763099

Group type: EXPERIMENTAL
Intervention: Scrambler therapy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Guideline-based drug management
Number of subjects: 52
Study: 20451294

Group type: EXPERIMENTAL
Intervention: Infection control education and training programme
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Usual practice continued
Number of subjects: 1131
Study: 18379854

Group type: EXPERIMENTAL
Intervention: Hydrophilic-coated sheaths (5 or 6 French)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Non-coated sheaths
Number of subjects: 200
Study: 16039603

Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy/Habit Reversal Training (ACT/HRT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 25
Study: 14679075

Group type: EXPERIMENTAL
Intervention: Cow-milk-free diet during last trimester of pregnancy
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cow milk introduction between 3 and 6 months
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Atopic disease
Number of subjects: 205
Study: 10773501

Group type: EXPERIMENTAL
Intervention: Droperidol (2.5 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (0.4 mg fentanyl in 40 ml of 0.125% bupivacaine)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Butorphanol (2 mg) and fentanyl (0.4 mg) in 40 ml of 0.125% bupivacaine
Number of subjects: 60
Study: 9053816

Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg once-a-day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lisinopril 20 mg
Number of subjects: 10
Study: 7953031

Group type: EXPERIMENTAL
Intervention: Home-based care (Daily Living Programme, DLP)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Standard in-patient and later out-patient care (control)
Number of subjects: 189
Study: 3501007

Group type: EXPERIMENTAL
Intervention: Whey-predominant formula
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Casein-predominant formula
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Breast-fed infants
Number of subjects: 111
Study: 27905499

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism treatment
Number of subjects: 541
Study: 25369393

Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dexamethasone 12 mg
Number of subjects: 27
Study: 22883658

Group type: EXPERIMENTAL
Intervention: Self-selected music during initial radiotherapy treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: No music during initial radiotherapy treatment (Control)
Number of subjects: 100
Study: 20550556

Group type: EXPERIMENTAL
Intervention: Early surgical intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continued pharmacotherapy
Number of subjects: 0
Study: 19063834

Group type: EXPERIMENTAL
Intervention: Yang deficiency constitution
Number of subjects: 110

Group type: COMPARATOR
Intervention: Normal constitution
Number of subjects: 110
Study: 15736890

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser alone (Group L: 10 pps, 200 mJ for 90 sec, n = 37)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Local minocycline administration following laser treatment (Group LP, n = 33)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Povidone‐iodine irrigation following laser treatment (Group LI, n = 33)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sham procedure (Control Group C, n = 32)
Number of subjects: 16
Study: 12525726

Group type: EXPERIMENTAL
Intervention: ASD
Number of subjects: 73

Group type: COMPARATOR
Intervention: TD
Number of subjects: 73

Group type: COMPARATOR
Intervention: DD
Number of subjects: 73
Study: 10730356

Group type: EXPERIMENTAL
Intervention: Patients with neck diseases
Number of subjects: 40

Group type: COMPARATOR
Intervention: Asymptomatic subjects
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Interexaminer reliability
Number of subjects: 40
Study: 9273227

Group type: EXPERIMENTAL
Intervention: Patients with arterial hypertension
Number of subjects: 36

Group type: COMPARATOR
Intervention: Patients without arterial hypertension
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study: 1670585

Group type: EXPERIMENTAL
Intervention: Interferon-alpha (18 mu daily) and zidovudine (600 mg daily)
Number of subjects: 56
Study: 6617065

Group type: EXPERIMENTAL
Intervention: Propranolol 180 mg/day twice a day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Propranolol 180 mg/day three times a day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both dosing regimens (twice and three times a day)
Number of subjects: 27
Study: 29247068

Group type: EXPERIMENTAL
Intervention: PF‐04236921 50 mg
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 29978322

Group type: EXPERIMENTAL
Intervention: r-batroxobin (2.5 BU/2.0 mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-batroxobin (5.0 BU/2.0 mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r-batroxobin (10.0 BU/2.0 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28531663

Group type: EXPERIMENTAL
Intervention: Ketogenic breakfast intervention (50-250 ml medium-chain triglyceride drink + 5-15 g amino acids) after overnight fast during radiotherapy.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Complete ketogenic diet during radiotherapy without fasting prior to RT fractions, supplemented with amino acids.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no dietary advice for ketogenic diet or carbohydrate reduction).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both intervention groups (1 and 2).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Intervention groups (1 and 2).
Number of subjects: 40
Study: 24421303

Group type: EXPERIMENTAL
Intervention: Three-month exercise intervention plus usual care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 120
Study: 22244599

Group type: EXPERIMENTAL
Intervention: Composite Asthma Severity Index (CASI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CASI
Number of subjects: 0
Study: 19349153

Group type: EXPERIMENTAL
Intervention: Interval-load training (ILT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Constant-load training (CLT)
Number of subjects: 42
Study: 17447657

Group type: EXPERIMENTAL
Intervention: Antidiabetic treatment with pioglitazone or glimepiride for 26 ± 2 weeks
Number of subjects: 151
Study: 15217057

Group type: EXPERIMENTAL
Intervention: Computer-generated visual displays
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Classroom demonstration
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Traditional lecture
Number of subjects: 116
Study: 11756064

Group type: EXPERIMENTAL
Intervention: 20 mg Zn/d for 14 d (Z group)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: 60000 retinol equivalents (200000 IU) vitamin A on day 14 (A group)
Number of subjects: 653

Group type: EXPERIMENTAL
Intervention: Zinc plus vitamin A (ZA group)
Number of subjects: 653

Group type: COMPARATOR
Intervention: Placebo syrup and placebo capsule (placebo group)
Number of subjects: 653
Study: 10483386

Group type: EXPERIMENTAL
Intervention: IAN/IO injection followed by repeated IO injection of 0.9 ml of 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 38

Group type: COMPARATOR
Intervention: IAN/IO injection followed by mock IO injection
Number of subjects: 38
Study: 8074256

Group type: EXPERIMENTAL
Intervention: norfloxacin in a single 800‐mg dose
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: norfloxacin, 400 mg twice a day for three days
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX), twice a day for three days
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: norfloxacin
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: trimethoprim (160 mg)‐sulfamethoxazole (800 mg) (TMP‐SMX)
Number of subjects: 154
Study: 2530714

Group type: EXPERIMENTAL
Intervention: Sulotroban (4 x 800 mg per day)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Sulotroban
Number of subjects: 107
Study: 196518

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.025 mg/70 kg body weight)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl (0.25 mg/70 kg body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sufentanil and Fentanyl
Number of subjects: 0
Study: 30741684

Group type: EXPERIMENTAL
Intervention: LY2599666 10 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY2599666 25 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY2599666 100 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY2599666 200 mg
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY2599666 25 mg once-weekly for 12 weeks
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: LY2599666
Number of subjects: 4
Study: 28452989

Group type: EXPERIMENTAL
Intervention: O/CMC/HA
Number of subjects: 80

Group type: COMPARATOR
Intervention: HA
Number of subjects: 80
Study: 25740607

Group type: EXPERIMENTAL
Intervention: CHO-BCAA
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CHO
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CHO-LEU
Number of subjects: 41

Group type: COMPARATOR
Intervention: PLC
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: RE
Number of subjects: 41
Study: 23837862

Group type: EXPERIMENTAL
Intervention: extensively hydrolysed whey formula (eWH)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: extensively hydrolysed casein formula (eCH)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: eWH with standard formula
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: eCH with standard formula
Number of subjects: 116
Study: 21762267

Group type: EXPERIMENTAL
Intervention: Rufloxacin (Group Ruf, n=70)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Levofloxacin (Group Lev, n=68)
Number of subjects: 138
Study: 19014837

Group type: EXPERIMENTAL
Intervention: LC15-0444 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LC15-0444 600 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: LC15-0444 (various doses 25, 50, 100, 200, 400, 600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: LC15-0444
Number of subjects: 60
Study: 16863968

Group type: EXPERIMENTAL
Intervention: Tecnis Z9000 IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: AR40e IOL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stabibag IOL
Number of subjects: 30
Study: 12752543

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish applications every 3 months for 24 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no varnish applications)
Number of subjects: 0
Study: 10691216

Group type: EXPERIMENTAL
Intervention: 5 mg morphine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 9
Study: 9226432

Group type: EXPERIMENTAL
Intervention: 0.02% zinc chloride
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 2 mg zinc acetate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0.5 mg zinc acetate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Chewing gum containing 0 mg zinc acetate
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Mouthrinses containing zinc
Number of subjects: 11

Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 11
Study: 8443808

Group type: EXPERIMENTAL
Intervention: IL-2 alone
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: IL-2 plus IFN-alpha
Number of subjects: 38

Group type: COMPARATOR
Intervention: IL-2 and IFN-alpha
Number of subjects: 38
Study: 3014770

Group type: EXPERIMENTAL
Intervention: Inactivated poliomyelitis vaccine (IPV)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Oral poliomyelitis vaccine (OPV)
Number of subjects: 160
Study: 29380915

Group type: EXPERIMENTAL
Intervention: 1% chocolate milk
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Milk samples collected in West region supermarkets
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fat content
Number of subjects: 136

Group type: COMPARATOR
Intervention: Macronutrient content
Number of subjects: 136
Study: 27729579

Group type: EXPERIMENTAL
Intervention: Enalapril 10-mg and folic acid 0.8-mg tablet
Number of subjects: 20702

Group type: COMPARATOR
Intervention: Enalapril 10-mg tablet alone
Number of subjects: 20702
Study: 25458657

Group type: EXPERIMENTAL
Intervention: Pharmacist case management
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Nurse case management
Number of subjects: 275
Study: 22696542

Group type: EXPERIMENTAL
Intervention: Small object lifting (wood-filled and brass-filled)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First lift of the large block (after lifting small objects)
Number of subjects: 0
Study: 19621225

Group type: EXPERIMENTAL
Intervention: Pegylated interferon alpha-2b (6 microg/kg/week for 8 weeks, then 3 microg/kg/week for up to 5 years)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Observation only (control group)
Number of subjects: 48
Study: 18773156

Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/d) plus Ezetimibe (10 mg/d)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Fluvastatin (80 mg/d)
Number of subjects: 305
Study: 16182346

Group type: EXPERIMENTAL
Intervention: Individualized dosage of 20 ml PCC based on target-INR of 2.1 or 1.5, initial-INR, and patient's body weight (group B)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Standard dosage of 20 ml PCC equivalent to about 500 IU factor IX (group A)
Number of subjects: 93
Study: 12817355

Group type: EXPERIMENTAL
Intervention: Joint consultation with cardiologists
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 306
Study: 10984002

Group type: EXPERIMENTAL
Intervention: Pramipexole (mean dose 0.70 mg/d, mean duration 24.4 weeks)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 32
Study: 8791959

Group type: EXPERIMENTAL
Intervention: 2 g mesalazine in 30 mL (group I, n = 10)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 4 g mesalazine in 60 mL (group II, n = 12)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 1 g mesalazine in 100 mL (group III, n = 9)
Number of subjects: 31
Study: 1612319

Group type: EXPERIMENTAL
Intervention: Erythromycin (3 mg/kg) administered IV for 15 minutes
Number of subjects: 17

Group type: COMPARATOR
Intervention: Saline administered IV for 15 minutes
Number of subjects: 17
Study: 6368353

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intensified conventional insulin treatment (CIT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both groups (CSII and CIT)
Number of subjects: 15
Study: 29747810

Group type: EXPERIMENTAL
Intervention: Intense care of oral hygiene (powered toothbrush and 1% chlorhexidine oral gel)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care of oral hygiene (manual toothbrush and toothpaste)
Number of subjects: 0
Study: 26963601

Group type: EXPERIMENTAL
Intervention: Group Behavioral Couples Therapy (G‐BCT) plus 12-step-oriented Individually Based Therapy (IBT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard Behavioral Couples Therapy (S‐BCT) plus Individually Based Therapy (IBT)
Number of subjects: 101
Study: 25332472

Group type: EXPERIMENTAL
Intervention: Water and education provision (WEP) group
Number of subjects: 240

Group type: COMPARATOR
Intervention: Education provision (EP) group
Number of subjects: 240
Study: 22742672

Group type: EXPERIMENTAL
Intervention: Distant Healing Intention (DHI) - Blinded group
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Distant Healing Intention (DHI) - Expectancy group (knowing they were receiving DHI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group (blinded and not receiving DHI)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: DHI under blinded conditions
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Belief in DHI efficacy
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Healers' perceptions of subjective 'contact' with participants
Number of subjects: 72
Study: 20456336

Group type: EXPERIMENTAL
Intervention: Risedronate 35 mg/week
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study: 18622068

Group type: EXPERIMENTAL
Intervention: Preemptive tramadol (iv injection of tramadol 100 mg 15 min before operation)
Number of subjects: 317

Group type: COMPARATOR
Intervention: Preventive tramadol (same dose of tramadol 100 mg 15 min before the end of the operation)
Number of subjects: 317
Study: 15685350

Group type: EXPERIMENTAL
Intervention: Ejaculated spermatozoa (Group 1)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Testicular spermatozoa (Group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 11889427

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10213466

Group type: EXPERIMENTAL
Intervention: TGF-beta1 in patients with microbiologically positive pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TGF-beta2 in patients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotrienes C4, D4, and E4 in patients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Leukotriene B4 in patients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMN elastase in patients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neopterin in patients with pneumonia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta1 with IL-8 levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta1 with percentage of granulocytes
Number of subjects: 0
Study: 7789488

Group type: EXPERIMENTAL
Intervention: Protriptyline 10 mg daily
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 2141757

Group type: EXPERIMENTAL
Intervention: 1.5 g n-3 fatty acids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 3 g n-3 fatty acids
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 6 g n-3 fatty acids
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 45
Study: 465277

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCT) 12.5 mg and 25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of HCT and metoprolol
Number of subjects: 0
Study: 31752859

Group type: COMPARATOR
Intervention: Nursing hours per patient day (NHPPD)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Proportion of nurse Bachelor hours
Number of subjects: 68
Study: 27443836

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 4262

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 4262
Study: 25872782

Group type: EXPERIMENTAL
Intervention: Electromagnetic guided bedside placement of nasoenteral feeding tubes
Number of subjects: 154

Group type: COMPARATOR
Intervention: Endoscopic placement of nasoenteral feeding tubes
Number of subjects: 154
Study: 23664327

Group type: EXPERIMENTAL
Intervention: IMN irradiation
Number of subjects: 1334

Group type: COMPARATOR
Intervention: No IMN irradiation (control)
Number of subjects: 1334
Study: 21899891

Group type: EXPERIMENTAL
Intervention: Kaltenborn manual therapy
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 29
Study: 19132974

Group type: EXPERIMENTAL
Intervention: Topical glucocorticoids (GC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Non-GC treated NP
Number of subjects: 39
Study: 16766330

Group type: EXPERIMENTAL
Intervention: Exomega milk applied twice a day for 2 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Cleansing bar only (non-treated group)
Number of subjects: 76
Study: 14722203

Group type: EXPERIMENTAL
Intervention: Infliximab plus MTX (3 mg/kg or 10 mg/kg every 4 or 8 weeks)
Number of subjects: 428

Group type: COMPARATOR
Intervention: MTX-only (placebo with MTX)
Number of subjects: 428